Medical isotope developer IsoRay Medical said it is forecasting cesium-131 seed implant sales for the treatment of prostate cancer to improve by 100% for its fiscal 2006 fourth quarter (end-June 30).
The Richland, WA-based firm said that it sold cesium-131 seed implants for 79 patients during its 2006 third quarter (end-March 31) and expects sales to increase to 160 units for the current fiscal period.
By AuntMinnie.com staff writers
June 20, 2006
Related Reading
IsoRay names Hunt as controller, April 19, 2006
IsoRay adds medical advisor, February 1, 2006
IsoRay, IBt notch technology agreement, January 3, 2006
IsoRay's cesium-131 seed available at NC hospital, November 29, 2005
IsoRay opens new production facility, November 3, 2005
Copyright © 2006 AuntMinnie.com
